[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

LU90718I2 - Visudyne-verteporfin et ses d-riv-s pharmaceutiquement acceptables - Google Patents

Visudyne-verteporfin et ses d-riv-s pharmaceutiquement acceptables

Info

Publication number
LU90718I2
LU90718I2 LU90718C LU90718C LU90718I2 LU 90718 I2 LU90718 I2 LU 90718I2 LU 90718 C LU90718 C LU 90718C LU 90718 C LU90718 C LU 90718C LU 90718 I2 LU90718 I2 LU 90718I2
Authority
LU
Luxembourg
Prior art keywords
tissues
cells
visudyne
verteporfin
pharmaceutically acceptable
Prior art date
Application number
LU90718C
Other languages
English (en)
Original Assignee
Univ British Columbia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ British Columbia filed Critical Univ British Columbia
Publication of LU90718I2 publication Critical patent/LU90718I2/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0485—Porphyrins, texaphyrins wherein the nitrogen atoms forming the central ring system complex the radioactive metal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0036—Porphyrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0058—Antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Optics & Photonics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
LU90718C 1988-07-19 2000-01-17 Visudyne-verteporfin et ses d-riv-s pharmaceutiquement acceptables LU90718I2 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/221,161 US4920143A (en) 1987-04-23 1988-07-19 Hydro-monobenzoporphyrin wavelength-specific cytotoxic agents

Publications (1)

Publication Number Publication Date
LU90718I2 true LU90718I2 (fr) 2001-03-01

Family

ID=22826617

Family Applications (1)

Application Number Title Priority Date Filing Date
LU90718C LU90718I2 (fr) 1988-07-19 2000-01-17 Visudyne-verteporfin et ses d-riv-s pharmaceutiquement acceptables

Country Status (10)

Country Link
US (1) US4920143A (fr)
EP (2) EP0352076B1 (fr)
AT (2) ATE209650T1 (fr)
AU (1) AU638675B2 (fr)
CA (1) CA1339927C (fr)
DE (3) DE68924215T2 (fr)
ES (2) ES2169060T3 (fr)
GR (1) GR3017426T3 (fr)
LU (1) LU90718I2 (fr)
NL (1) NL300037I2 (fr)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5095030A (en) * 1987-01-20 1992-03-10 University Of British Columbia Wavelength-specific cytotoxic agents
USRE38994E1 (en) 1988-07-20 2006-02-28 Health Research, Inc. Pyropheophorbides conjugates and their use in photodynamic therapy
US5002962A (en) * 1988-07-20 1991-03-26 Health Research, Inc. Photosensitizing agents
US5198460A (en) * 1988-07-20 1993-03-30 Health Research Inc. Pyropheophorbides and their use in photodynamic therapy
USRE39094E1 (en) * 1988-07-20 2006-05-09 Health Research, Inc. Pyropheophorbides and their use in photodynamic therapy
WO1990015059A1 (fr) * 1989-06-07 1990-12-13 The University Of British Columbia Derives de porphyrine de diels-alder utilises comme photosensibilisateurs
US5087636A (en) * 1990-02-20 1992-02-11 University Of British Columbia Method to destroy malignant cells in mononuclear cell populations
US5214036A (en) * 1990-03-08 1993-05-25 University Of British Columbia Benzoporphyrin derivatives for photodynamic therapy
US5053423A (en) * 1990-03-22 1991-10-01 Quadra Logic Technologies Inc. Compositions for photodynamic therapy
US5120649A (en) * 1990-05-15 1992-06-09 New York Blood Center, Inc. Photodynamic inactivation of viruses in blood cell-containing compositions
GB9014307D0 (en) * 1990-06-27 1990-08-15 Scient Generics Ltd Method of treatment and compositions therefor
US5219878A (en) * 1990-10-05 1993-06-15 Queen's University Tetrapyrrole hydroxyalkylamide photochemotherapeutic agents
US5435307A (en) * 1991-03-29 1995-07-25 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Surface fluorescent monitor
CA2087902C (fr) * 1992-02-05 2006-10-17 Narendra Raghunathji Desai Compositions liposomiques renfermant des photosensibilisateurs a base de porphyrine
US6890555B1 (en) * 1992-02-05 2005-05-10 Qlt, Inc. Liposome compositions of porphyrin photosensitizers
US5330741A (en) * 1992-02-24 1994-07-19 The Regents Of The University Of California Long-wavelength water soluble chlorin photosensitizers useful for photodynamic therapy and diagnosis of tumors
CA2097280A1 (fr) * 1992-06-01 1993-12-02 Sandor G. Vari Appareil et methode d'utilisation d'une aiguille a biopsie dont la visibilite est accrue par un agent photosensibilisant fluorescent
AU4695493A (en) * 1992-08-17 1994-03-15 Quadra Logic Technologies Inc. Method for destroying or inhibiting growth of unwanted cells or tissues
US5798349A (en) 1994-03-14 1998-08-25 The General Hospital Corporation Use of green porphyrins to treat neovasculature in the eye
US6551618B2 (en) * 1994-03-15 2003-04-22 University Of Birmingham Compositions and methods for delivery of agents for neuronal regeneration and survival
ITFI940095A1 (it) * 1994-05-23 1995-11-23 Molteni & C Coniugati fotodinamici aventi proprieta' biocide
US5882328A (en) * 1995-01-13 1999-03-16 Qlt Phototherapeutics, Inc. Method to prevent transplant rejection
US5789433A (en) * 1995-01-17 1998-08-04 Quadra Logic Technologies, Inc. Green porphyrins as immunomodulators
US6096776A (en) * 1995-01-17 2000-08-01 Qlt Phototherapeutics, Inc. Green porphyrins as immunomodulators
US6107325A (en) * 1995-01-17 2000-08-22 Qlt Phototherapeutics, Inc. Green porphyrins as immunomodulators
DE19514088A1 (de) 1995-04-13 1996-10-17 Deutsches Krebsforsch Konjugat zur Behandlung von Entzünduns-, Infektions- und/oder Hauterkrankungen
US5707608A (en) * 1995-08-02 1998-01-13 Qlt Phototherapeutics, Inc. Methods of making liposomes containing hydro-monobenzoporphyrin photosensitizer
WO1997026885A1 (fr) * 1996-01-23 1997-07-31 The General Hospital Corporation Doing Business As Massachusetts General Hospital Combinaison des colorants benzophenothiazine et benzoporphyrine pour le traitement photodynamique de tumeurs
WO1999013943A1 (fr) 1996-03-05 1999-03-25 Ekos Corporation Ensemble a ultrasons destine a etre utilise avec des medicaments actives par la lumiere
US5693789A (en) * 1996-04-10 1997-12-02 Abbott Laboratories Process for the preparation of a protoporphyrin
US5834503A (en) * 1996-06-14 1998-11-10 Qlt Phototherapeutics, Inc. Methods to treat arterial plaque
US6043237A (en) * 1996-12-10 2000-03-28 Qlt Phototherapeutics, Inc. Use of photodynamic therapy for prevention of secondary cataracts
EP0983273B8 (fr) * 1997-05-07 2002-10-09 QLT Inc. Esters d'ethyleneglycol de derives de monohydrobenzopophyrine utilises comme agents photosensibles
US5880145A (en) * 1997-05-07 1999-03-09 The University Of British Columbia Class of benzoporphyrin derivative photoactive compounds
US6756396B1 (en) * 1997-05-07 2004-06-29 Qlt Inc. Ethylene glycol esters as photoactive agents
ATE253068T1 (de) * 1997-05-07 2003-11-15 Univ British Columbia Ein klasse von benzoporphyrin derivate photowirksame verbindungen
WO1999004857A1 (fr) 1997-07-28 1999-02-04 Novartis Ag Dispositif et procede pour l'irradiation oculaire d'un patient dans le cadre d'une therapie photodynamique
CA2221912A1 (fr) * 1997-11-21 1999-05-21 David Dolphin Agents photosensibilisants dont les proprietes de biodistribution et d'absorption de lumiere sont ameliorees
US6316215B1 (en) 1999-12-27 2001-11-13 Edwin L. Adair Methods of cancer screening utilizing fluorescence detection techniques and selectable imager charge integration periods
EP1045704B1 (fr) 1998-01-06 2004-09-22 Cerus Corporation Procedes permettant d'inhiber les inactivateurs de pathogenes dans des matieres biologiques
US20030215421A1 (en) * 1999-07-21 2003-11-20 Mcdonald John R. Methods and compositions for treating secondary tissue damage and other inflammatory conditions and disorders
US7157418B1 (en) 1998-07-22 2007-01-02 Osprey Pharmaceuticals, Ltd. Methods and compositions for treating secondary tissue damage and other inflammatory conditions and disorders
WO2000061585A2 (fr) 1999-04-14 2000-10-19 The University Of British Columbia (Ubc) Modification de macrocycles polypyrroliques par utilisation d'une reaction de cycloaddition 1,3-dipolaire
US20020022032A1 (en) * 1999-04-23 2002-02-21 Curry Patrick Mark Immuno-adjuvant PDT treatment of metastatic tumors
US7122568B1 (en) 1999-11-17 2006-10-17 Qlt, Inc. Use of low-dose PDT to inhibit restenosis
US6750037B2 (en) 1999-12-27 2004-06-15 Edwin L. Adair Method of cancer screening primarily utilizing non-invasive cell collection, fluorescence detection techniques, and radio tracing detection techniques
US6984498B2 (en) * 1999-12-27 2006-01-10 Adair Edwin L Method of cancer screening primarily utilizing non-invasive cell collection, fluorescence detection techniques, and radio tracing detection techniques
US6190877B1 (en) 1999-12-27 2001-02-20 Edwin L. Adair Method of cancer screening primarily utilizing non-invasive cell collection and fluorescence detection techniques
BR0109499A (pt) * 2000-03-24 2002-12-10 Novartis Ag Tratamento melhorado de neovascularização
US7282215B2 (en) 2000-05-08 2007-10-16 The University Of British Columbia Supports for photosensitizer formulations
US6984395B2 (en) * 2001-04-11 2006-01-10 Qlt, Inc. Drug delivery system for hydrophobic drugs
US20030103995A1 (en) 2001-06-04 2003-06-05 Hamblin Michael R. Detection and therapy of vulnerable plaque with photodynamic compounds
CA2466103C (fr) * 2001-11-02 2010-06-15 The Governors Of The University Of Alberta Compositions de micelle comportant des phospholipides pegylates et un photosensibilisateur
NZ533036A (en) * 2001-11-09 2006-04-28 Quadra Logic Tech Inc Compositions comprising a photosensitizer and skin penetration enhancer and their use in photodynamic treatment for alopecia cancer acne psoriasis dermatitis ablation and promoting hair growth
EP1374912B1 (fr) * 2002-06-21 2006-08-16 Edwin L. Adair Utilisations de métalloporphyrines pour le traitement de lésions artériosclérotiques
AU2003301267A1 (en) * 2002-10-18 2004-05-04 The Regents Of The University Of California Photodynamic therapy for ocular neovascularization
US20040220167A1 (en) * 2003-05-02 2004-11-04 Nasrollah Samiy Methods of treating neuralgic pain
CA2437638A1 (fr) * 2003-08-20 2005-02-20 John Robert North Therapie photodynamique
CA2457214A1 (fr) 2004-02-06 2005-08-06 Qlt Inc. Therapie photodynamique pour le traitement de l'acne
WO2006020979A2 (fr) * 2004-08-13 2006-02-23 Yale University Conjugues du facteur vii permettant de traiter selectivement des troubles de la neovascularisation
AU2005302256B2 (en) 2004-10-29 2011-01-20 Cerus Corporation Improved quenching methods for red blood cell inactivation process
KR101742533B1 (ko) 2008-04-09 2017-06-01 세루스 코포레이션 적혈구 병원체 불활성화를 위한 개선된 퀀칭 방법
WO2011009020A2 (fr) 2009-07-16 2011-01-20 Mallinckrodt Inc. Composés et compositions pour une utilisation en photothérapie et dans le traitement d'une maladie néovasculaire oculaire et de cancers
BR112013017953A2 (pt) 2011-01-13 2017-08-29 Quadra Logic Tech Inc Composição farmacêutica, formulação tópica, método, e, composição fotossensibilizadora
SG11201405553YA (en) 2012-03-08 2014-11-27 Halozyme Inc Conditionally active anti-epidermal growth factor receptor antibodies and methods of use thereof
BR112015000383A2 (pt) 2012-07-11 2017-06-27 Dermira Inc composição farmacêutica, e, métodos para preparação de uma composição farmacêutica, para reduzir a taxa de excreção de sebo das glândulas sebáceas na pele de um indivíduo e para tratamento da acne
JP6282745B2 (ja) 2013-09-12 2018-02-21 ハロザイム インコーポレイテッド 修飾抗上皮成長因子受容体抗体およびその使用法
WO2017161206A1 (fr) 2016-03-16 2017-09-21 Halozyme, Inc. Conjugués contenant des anticorps à activité conditionnelle ou des fragments de liaison à un antigène associés, et procédés d'utilisation
MA47786A (fr) 2017-03-14 2020-01-22 Ohio State Innovation Foundation Méthodes et compositions se rapportant à des immunoconjugués igg3 ciblant le facteur tissulaire
CN112204048A (zh) 2017-12-15 2021-01-08 朱诺治疗学股份有限公司 抗cct5结合分子及其使用方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2951800A (en) * 1957-11-13 1960-09-06 Monsanto Chemicals Photoxidation processes utilizing improved catalysts
WO1984001382A1 (fr) * 1982-09-27 1984-04-12 Oncology Research & Dev Inc Derive d'hematoporphirine purifie utilise dans le diagnostic et le traitement de tumeurs et procede
US4649151A (en) * 1982-09-27 1987-03-10 Health Research, Inc. Drugs comprising porphyrins
US4675338A (en) * 1984-07-18 1987-06-23 Nippon Petrochemicals Co., Ltd. Tetrapyrrole therapeutic agents
AU583854B2 (en) * 1984-09-13 1989-05-11 Cytogen Corporation Antibody therapeutic agent conjugates
US4883790A (en) * 1987-01-20 1989-11-28 University Of British Columbia Wavelength-specific cytotoxic agents

Also Published As

Publication number Publication date
DE10199008I2 (de) 2004-10-14
EP0352076A2 (fr) 1990-01-24
US4920143A (en) 1990-04-24
CA1339927C (fr) 1998-06-23
DE10199008I1 (de) 2003-06-12
ES2080745T3 (es) 1996-02-16
ATE127696T1 (de) 1995-09-15
EP0352076A3 (fr) 1991-07-17
DE68929351D1 (de) 2002-01-10
NL300037I1 (nl) 2001-03-01
GR3017426T3 (en) 1995-12-31
AU3825889A (en) 1990-02-08
EP0641796A1 (fr) 1995-03-08
DE68929351T2 (de) 2002-05-08
EP0641796B1 (fr) 2001-11-28
NL300037I2 (nl) 2001-08-01
EP0352076B1 (fr) 1995-09-13
DE68924215D1 (de) 1995-10-19
ES2169060T3 (es) 2002-07-01
ATE209650T1 (de) 2001-12-15
DE68924215T2 (de) 1996-02-15
AU638675B2 (en) 1993-07-08

Similar Documents

Publication Publication Date Title
LU90718I2 (fr) Visudyne-verteporfin et ses d-riv-s pharmaceutiquement acceptables
US5913884A (en) Inhibition of fibrosis by photodynamic therapy
Fingar et al. Drug and light dose dependence of photodynamic therapy: a study of tumor and normal tissue response
EP0947222B1 (fr) Procédé d'activation d'agents photosensibles
KR970705413A (ko) 암의 광역학요법용 새로운 로다민 유도체 및 백혈병의 시험관내 정화(novel rhodamine derivatives for photodynamic therapy of cancer and in vitro purging of the leukemias)
EP0425566A4 (en) New photosensitizing agents
Berns et al. Response of psoriasis to red laser light (630 nm) following systemic injection of hematoporphyrin derivative
Biolo et al. Photodynamic therapy of B16 pigmented melanoma with liposome‐delivered Si (IV)‐naphthalocyanine
Razum et al. SnET2: clinical update
EP1120119A4 (fr) Remedes pour photochimioterapie
Dillon et al. In vitro and in vivo protection against phototoxic side effects of photodynamic therapy by radioprotective agentswr–2721 andwr–77913
CA2270558A1 (fr) Traitement de maladies auto-immunes par photochimiotherapie
PT1267931E (pt) Derivados de rodamina para o diagnostico e tratamento fotodinamicos
Baker et al. Otolaryngology/Head and Neck Surgery: Topical Gentamicin Prophylaxis with Tympanostomy
WO1992000106A3 (fr) Methode de traitement et compositions utilisees a cet effet
IL121440A0 (en) The use of 1,3,4,6-tetrahydroxy-helianthrone and its derivatives in photodynamic therapy and certain such novel derivatives
Land Porphyrin phototherapy of human cancer
Okuda et al. Experimental and clinical studies on HPD-photoradiation therapy for upper gastrointestinal cancer
Davis et al. Effects of photosensitizer (hematoporphyrin derivative‐HPD) and light dose on vascular targets in the albino mouse ear
Okuda for Early Gastric Cancer
Tomio et al. Effect of hematoporphyrin and red light on AH-130 solid tumors in rats
RU2146159C1 (ru) Способ фотодинамической терапии злокачественных новообразований
US6586419B1 (en) Phototherapeutic inactivation of ocular viruses
RU2113254C1 (ru) Способ лечения злокачественных опухолей методом фотодинамической терапии
Nyamekye Vascular and other non-tumour applications of photodynamic therapy